2010-05-31 - Medesis Pharma, the French based pharmaceutical company, announces the successful completion of a phase I clinical trial of NP01, a first in class anti-diabetic for the treatment of type 2 diabetes mellitus.The objective of this randomised, double blind, placebo controlled study was to evaluate the tolerability of NP01 in healthy male volunteers following single and repeat administration of 180ug of the drug’s active ingredient, vanadium.
The company reported that there were no serious adverse events and that the drug was well tolerated both after single and repeat administration...
[...]
...About Medesis Pharma
Medesis Pharma is a clinical stage pharmaceutical company specialising in the development of a wide range of therapeutic agents based upon propriety Aonys® drug delivery technology. Aonys® is particularly applicable to metal and oligonucleotide active ingredients... Medesis Pharma's Press Release -
...About Medesis Pharma
Medesis Pharma is a clinical stage pharmaceutical company specialising in the development of a wide range of therapeutic agents based upon propriety Aonys® drug delivery technology. Aonys® is particularly applicable to metal and oligonucleotide active ingredients... Medesis Pharma's Press Release -
